Minister highlights RDI fund, private participation in space and nuclear sectors, and calls for faster reforms to improve ease of research in India
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Board approves five-year appointment, subject to shareholder nod through postal ballot
Subscribe To Our Newsletter & Stay Updated
